Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic CarcinomaAlexander Stoeck, Sriram Sathyanarayanan, Serguei Lejnine et al.|Cancer Discovery|2014Cited by 154
Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Christopher Winter et al.|Clinical Cancer Research|2014Cited by 56
Abstract 3478: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical modelsMarlene C. Artime, Brian B. Haines, Samuel C. Blackman et al.|Cancer Research|2010Cited by 1
Abstract 1868: Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinomaBrian B. Haines, Sriram Sathyanarayanan, Michael J. Wick et al.|Cancer Research|2012Cited by 1
Supplementary Figure 4 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0